Advanced Glycosylation End Product Specific Receptor (AGER) Antibody
741€ (1 ml)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Name
Advanced Glycosylation End Product Specific Receptor (AGER) Antibody
Category
Primary Antibodies
Provider
Abbexa
Reference
abx171123
Tested Applications
WB, IHC, IF/ICC
Description
This product is currently in development. The lead time for this product may be several months. Please contact us at
Documentos del producto
Instrucciones
Data sheet
Especificaciones del producto
| Category | Primary Antibodies |
| Immunogen Target | Target: Advanced Glycosylation End Product Specific Receptor (AGER) |
| Host | Mouse |
| Reactivity | Human |
| Recommended Dilution | WB: 0.01-2 µg/ml, IHC: 5-20 µg/ml, IF/ICC: 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Monoclonal |
| Conjugation | Unconjugated |
| Purification | Purified by Protein A and Protein G affinity chromatography. |
| Size 1 | 1 ml |
| Form | Liquid |
| Tested Applications | WB, IHC, IF/ICC |
| Buffer | 0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol. |
| Availability | Please enquire. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| Alias | RAGE,SCARJ1,sRAGE |
| Background | Antibody anti-AGER |
| Status | RUO |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. |
Background
AGER, also known as RAGE (Receptor for Advanced Glycation End Products), is a transmembrane receptor belonging to the immunoglobulin superfamily that binds to AGEs and other ligands such as S100 proteins, HMGB1, and amyloid-β. AGER is widely expressed, particularly in the endothelium, lungs, brain, and immune cells, and plays a critical role in inflammatory and oxidative stress signaling. Binding of AGEs to AGER activates downstream pathways, including NF-κB, MAPK, and JAK/STAT, leading to the production of pro-inflammatory cytokines and reactive oxygen species. Overexpression or chronic activation of AGER is associated with diseases such as diabetes complications, atherosclerosis, Alzheimer’s disease, and cancer, where it exacerbates inflammation and tissue damage. AGER is a promising therapeutic target for reducing AGE-mediated pathologies and modulating immune and metabolic dysfunction.
Productos relacionados
Advanced Glycosylation End Product-Specific Receptor (AGER) Antibody
AGER Antibody is a Rabbit Polyclonal antibody against AGER. The advanced glycosylation end product (AGE) receptor encode…
Ver producto
Advanced Glycosylation End Product-Specific Receptor (AGER) Antibody
Advanced Glycosylation End Product-Specific Receptor (AGER) Antibody is a Rabbit Polyclonal antibody for the detection o…
Ver producto
Advanced Glycosylation End Product-Specific Receptor (AGER) Antibody
AGER encodes a member of the immunoglobulin superfamily of cell surface molecules. It is a receptor for various molecule…
Ver producto